Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

National Geographic Announces QUEENS, the First-Ever Natural History Docuseries Where Female Animals Reign Supreme



Reading Time: 3 minutes

Six-part Series Breaks a Gender Barrier, Marking the First Women-led
Production Team to Capture A New Perspective on Nature

WASHINGTON–(BUSINESS WIRE)–Never before has a women-led production team set out to capture the
wondrous beauty of the natural world, and never before has natural
history storytelling focused solely on matriarchal societies… until now.

National Geographic, world renowned for its rich tradition in natural
history storytelling and cinematic craft, announces QUEENS, an
epic, six-part natural history docuseries that follows six powerful
sisterhoods within the animal kingdom where females rule. The all-women
visionaries behind the series draw on their female intuitions to shine a
fresh light on the natural world, revealing unique feminine behaviors in
six distinct animal communities: hyenas, elephants, ring-tailed lemurs,
insects, primates and orcas.

QUEENS, which began production this spring will air globally
in 172 countries and 43 languages, is a mammoth undertaking; crews are
estimated to spend at least 300 days filming each of the six episodes in
order to paint intimate portraits of each queen and the sisterhood she

QUEENS is a wild departure from anything you’ve ever
experienced with natural history storytelling,” says Vanessa Berlowitz,
series executive producer, Wildstar Films. “We’re accustomed to a
narrative where the male animal voice often outshines that of the
misperceived ‘gentler’ sex. In QUEENS, females drive
the story: the most accomplished women in the industry get behind the
camera to turn things on their heads, revealing surprising insights into
how females rise to power, often relying on cooperation and wisdom over
brute strength to get ahead.”

“With QUEENS, National Geographic challenges a
historical bias in wildlife storytelling that favors masculine
societies,” says Janet Han Vissering, senior vice president of
development and production, National Geographic. “The assembly of
first-ever women-led production team will bring a new perspective to
telling these intimate narratives. Scientifically, women score higher
for emotional and social intelligence, so it will be fascinating to see
how the team will read relationships to underscore the nuances of how
female-bonded societies operate.”

Each episode devotes itself to discovering just why the title of queen
is so coveted and tenuous. While getting to the top signifies power,
holding rank is far from easy. Every day brings challenges – and
challengers – to a queen’s rule. How she remains dominant depends on
individual personality, loyalty, cooperation, politics, strength and

Despite major behavioral differences among each society – for example,
bees, wasps and ants are slaves to a single dictatorial queen, while
elephants choose the oldest and wisest of their matriarch – there’s at
least one thing that each queen has in common: family comes first. In QUEENS, nothing
outmatches the powerful bonds of sisterhood.

The production team is led by Berlowitz, CEO of Wildstar Films and
series executive producer, and also boasts some of the world’s most
renowned, accomplished cinematographers, including Sophie Darlington (“Our
Planet,” “Dynasties,” Disneynature’s “Penguins”)
and Justine
Evans (“Planet Earth,” “Frozen Planet,” “Life”).

“This series is full of possibilities and will offer a contemporary
perspective on nature with the ambition to build industry legacy through
diversity, collaboration and inclusiveness,” says Darlington. “It’s so
exciting to create a project with such a talented team; we share a
strong commitment to the environment and believe that engaging women is
key to saving the planet.”

QUEENS features state-of-the-art technology, including
remote camera systems, the latest drones, cameras that operate in
virtual darkness and gyrostabilized cameras for close-up, immersive
filming. All the equipment used throughout each episode aims to give the
viewer a profound understanding of the secret relationships within each
queen’s sisterhood.

QUEENS is produced by Wildstar Films for National Geographic. For
Wildstar Films, Vanessa Berlowitz is executive producer. Janet Han
Vissering is senior vice president of development and production,
National Geographic.

Link to photos:

About National Geographic Partners LLC

National Geographic Partners LLC (NGP), a joint venture between Disney
and the National Geographic Society, is committed to bringing the world
premium science, adventure and exploration content across an unrivalled
portfolio of media assets. NGP combines the global National Geographic
television channels (National Geographic Channel, Nat Geo Wild, Nat Geo
Mundo, Nat Geo People) with National Geographic’s media and
consumer-oriented assets, including National Geographic magazines;
National Geographic studios; related digital and social media platforms;
books; maps; children’s media; and ancillary activities that include
travel, global experiences and events, archival sales, licensing and
e-commerce businesses. Furthering knowledge and understanding of the
world has been the core purpose of National Geographic for 131 years,
and now it is committed to going deeper, pushing boundaries, going
further for consumers… all while reaching millions of people around the
world in 172 countries and 43 languages every month. NGP returns 27
percent of its proceeds to the nonprofit National Geographic Society to
fund work in the areas of science, exploration, conservation and
education. For more information visit

About Wildstar Films

Wildstar Films is a production company based in Bristol, UK. We are a
team of passionate film makers committed to creating films to inspire
global audiences about the natural world. Our Emmy and BAFTA-Award
winning staff have set new standards in wildlife film-making as show
runners, producers, directors and writers. We have many long standing
alliances with cutting-edge technology and camera companies, which also
keep us at the forefront of innovation. Credits include “Planet Earth,”
Frozen Planet,” “ Enchanted Kingdom,” “Wild Yellowstone,” Disneynature’s
“Earth,” “Chimpanzee” and “Monkey Kingdom.”


Jennifer DeGuzman, National Geographic, 212-656-0713, [email protected]
Kouperstein, National Geographic, 202-912-6543, [email protected]

Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493


Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits




HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.   

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.

Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.   

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025


Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.


Cision View original content:

Continue Reading


Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer




DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.

Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.

“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected] 

View original content:

Continue Reading


Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028



Continue Reading

Trending on Grassnews Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania